Fiche publication
Date publication
juillet 2016
Journal
Journal of the National Cancer Institute
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MOUILLET Guillaume
,
Dr VERNEREY Dewi
Tous les auteurs :
Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Zaanan A
Lien Pubmed
Résumé
Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant chemotherapy while preliminary data suggest chemosensitivity to oxaliplatin. We assessed the efficacy of fluoropyrimidine with and without oxaliplatin in a large cohort of dMMR CC patients.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Brain Neoplasms, Chemotherapy, Adjuvant, Colonic Neoplasms, drug therapy, Colorectal Neoplasms, Female, Germ-Line Mutation, Humans, Kaplan-Meier Estimate, Male, Microsatellite Instability, Middle Aged, Neoplasm Staging, Neoplastic Syndromes, Hereditary, Organoplatinum Compounds, administration & dosage, Pyrimidines, administration & dosage, Retrospective Studies, Treatment Outcome
Référence
J. Natl. Cancer Inst.. 2016 Jul;108(7):
